Eden Research Plc · LSE:EDEN
Eden Research — Shareholder Meeting (September 2026)
27 slides from Eden Research's shareholder meeting presentation, Sep 29, 2026
Slide 1: Annual General Meeting 2026
Annual General Meeting 2026 Eden Research plc · AIM: EDEN 29 September 2026
Slide 2: Important notice: Forward-looking statements
Important notice Forward-looking statements This presentation has been prepared by Eden Research plc (the “Company”) for its Annual General Meeting on 29 September 2026. It does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or s
Slide 3: Introducing Eden BioSolutions plc
Introducing Eden BioSolutions plc A new identity for the business we have become - full launch by late November 2026 We develop and sell sustainable crop protection solutions for professional agriculture including fungicides, nematicides, seed treatments and insecticides…. We provide solutions for t
Slide 4: Agenda
Agenda Today 01 The year in review 02 Our products in the field 03 Pipeline: proceeds at work 04 Outlook 05 Questions
Slide 5: Eden at a glance: The UK's only quoted pure-play in biopesticides
Eden at a glance The UK’s only quoted pure-play in biopesticides 35 100+ 67 7+ 100% countries with product crop-use approvals patents granted commercial partners, of revenue from green authorisations and pending including global majors products (LSE Green Economy Mark) 01 Residue-free 02 Plastic-fre
Slide 6: The year in review
01 The year in review
Slide 7: What we told you at last year's AGM, and what happened
Accountability What we told you at last year’s AGM, and what happened We said (June 2025) Timing What happened Status Major label extensions for Mevalone® (e.g. France downy and powdery mildew label granted January 2026, Q3 2025 Delivered France) plus California, Italy (3LOGY) and Chile (Novellus+)
Slide 8: Revenue grew and the balance sheet was strengthened after the period
Results · 15 months to 31 March 2026 Revenue grew and the balance sheet was strengthened after the period £4.9m £3.9m £2.2m £(2.9)m £1.5m Revenue Product sales Gross profit Operating loss Period-end cash CY2024: £4.3m CY2024: £3.6m CY2024: £1.9m CY2024: £(2.2)m Before the £10.8m raise Why a 15-month
Slide 9: Product sales have grown 2.6 times since 2019/20
Product sales · by season (April to March) Product sales have grown 2.6 times since 2019/20, with some seasonal volatility Product sales by season, €m (total under each season) €4m 2.6× product sales in 2025/26 (€4.1m) versus 2019/20 (€1.6m) €3m €2m 17% compound annual growth over the six seasons €1
Slide 10: Soil health products now share the load
Product mix Soil health products now share the load, so one weak season matters less Foliar Health Soil Health Products 3.1 2.9 2.1 1.6 1.4 1.4 1.0 1.0 1.2 1.0 0.3 0.3 <0.1 19/20 20/21 21/22 22/23 23/24 24/25 25/26 19/20 20/21 21/22 22/23 23/24 24/25 25/26 Mevalone® and related biofungicides. Sales
Slide 11: Each new product adds another layer of sales on top of the last
Building the revenue base Each new product adds another layer of sales on top of the last Illustrative only: layer heights are not to scale and this is not a forecast Insecticide Launch est. 2031 · €30.4m peak potential Late blight fungicide Regulatory submission targeted 2027 Mevalone®, Cedroz , Ec
Slide 12: The majority of the £10.8m raise is allocated to four programmes
Capital allocation The majority of the £10.8m raise is allocated to four programmes and the renewal of the actives in the EU What the money buys Late blight fungicide £3.9m faster route to market for the insecticide 2–3 years and late blight programmes than self- funding Septoria (wheat) fungicide £
Slide 13: Our products in the field
02 Our products in the field
Slide 14: France's downy mildew label opens a €2.4bn market to Mevalone
Mevalone® · biofungicide France’s downy mildew label opens a €2.4bn market to Mevalone® Disease incidence, average of 13 trials in southern Europe (lower is better) 82% €2.4bn addressable downy mildew market: France €272m, southern Europe €592m, US €144m, rest of world €1.4bn 30% 27% €38.2m 18% Eden
Slide 15: Three products on sale or approved, sold through partners
Commercial portfolio Three products on sale or approved, sold through partners who already reach growers Mevalone® Cedroz Ecovelex Biofungicide · commercial Bio-nematicide · commercial Seed treatment · in registration • Botrytis, powdery and downy mildew • Root-knot nematodes in high-value • Bird re
Slide 16: Pipeline: proceeds at work
03 Pipeline: proceeds at work
Slide 17: Experimental products held back severe late blight in UK and Dutch trials
Late blight · potato field trials, September 2026 Used alone, our experimental products held back severe late blight in UK and Dutch trials Both trials • High disease pressure at both sites • Products applied as a stand-alone treatment EDN037 • Treated plots stayed green while ERP054012 untreated pl
Slide 18: Untreated severity reached 81%, yet gaps + ERP054004 still gave 55% efficacy
Late blight · potato field trial, Bari, Italy, 2026 Untreated severity reached 81%, yet gaps + ERP054004 still gave 55% efficacy at the final assessment Abbott's efficacy on disease severity by programme and assessment, Bari, % 81% 5–7 DAC 5–7 DAD 5–7 DAE 5–7 DAF disease severity on untreated plots
Slide 19: Experimental + oil kept banana leaves almost free of black sigatoka
Black sigatoka · banana leaf assessments, 2026 Experimental + oil kept banana leaves almost free of black sigatoka 35 days after application Untreated Oil Experimental + oil Mancozeb + oil 35 days Before after application, the experimental + oil leaf still shows almost no lesions • Oil alone and man
Slide 20: Insecticide: lab results are strong and partner talks are in final stages
Insecticide programme Insecticide: lab results are strong and partner talks are in the final stages Control of cabbage stem flea beetle, lab trials 88% 76% 81% Untreated: spider mites healthy Treated: adults dead, body breaking Pyrethroid reference Late-stage candidate Early-stage candidate down (9
Slide 21: In wheat, our developmental fungicide performed in line with the biological reference
Cereals · Mevalone® in wheat In wheat, our developmental fungicide performed in line with the leading biological reference Efficacy on disease severity (%), flag leaf, summary of trials Why this matters 97 92 93 • Cereal fungicides are one of Europe’s largest crop protection markets, and conventiona
Slide 22: Three products earning revenue, four more moving toward market
Pipeline Three products earning revenue, four more moving toward market Product Target Stage Next milestone Peak sales Fungal diseases of grapes, fruit and Mevalone® vegetables Commercial Colombia launch Q4 2026; €52.9m Commercial developments Cedroz Nematodes; potato wireworm Commercial 2026/27 €14
Slide 23: Outlook
04 Outlook
Slide 24: Milestones we expect to report over the next 18 months
What to watch for Milestones we expect to report over the next 18 months By the end of 2026 2027 2028 • Commercial agreement for the • Late blight regulatory submission • Insecticide regulatory submission insecticide • Submission for wheat • Cereals and banana programmes • Full EU approval of Ecovel
Slide 25: Eden has the most revenue and registrations of the three, at the lowest valuation
Listed biocontrol peers Eden has the most revenue and registrations of the three, at the lowest valuation Eden Biotalys Amoéba AIM: EDEN · London BTLS · Euronext Brussels ALMIB · Euronext Paris Plant-derived terpenes Protein-based biocontrol Amoeba lysate biocontrol Capital raised since 2013 £38m £1
Slide 26: Why Eden is well placed
Why Eden Why Eden is well placed 01 One of few chances to capitalise on the movement to sustainable agriculture. The only UK-quoted pure-play in biopesticides 02 Registered products 35 countries and 100+ crop-use approvals, sold by regional and global leaders 03 Tailwinds Conventional actives withdr
Slide 27: Thank you
Thank you Questions welcome eden BioSolutions